The use of excessively fragile efficacy data and delays in sponsors’ presenting living proof from post-approval trials, as well as the approval of some crucial drugs based on preliminary clinical evidence, continue to be controversial issues. Under the programme, the FDA has approved dozens of beneficial medicines, many of which were able to establish their […]
The post Issues With Accelerated Approval Remain A Problem For FDA first appeared on World Pharma Today.This post first appeared on Leading Pharmaceutical Industry Online Platform, please read the originial post: here